NCT03351647View on ClinicalTrials.gov

Predictive Factors of Clinical Response to Ustekinumab in Active Crohn's Disease

CompletedOBSERVATIONAL
Enrollment

18

Participants

Timeline

Start Date

February 14, 2018

Primary Completion Date

August 29, 2018

Study Completion Date

September 23, 2019

Conditions
Crohn Disease
Interventions
BIOLOGICAL

Evaluation of biological predictive factors of clinical response to ustekinumab

The clinical response is defined as a decrease in the Crohn's Disease Activity Index (CDAI) score ≥ 100 points or a decrease in the HBI score ≥ 3 points.

Trial Locations (1)

69495

Centre hospitalier Lyon Sud, Pierre-Bénite

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT03351647 - Predictive Factors of Clinical Response to Ustekinumab in Active Crohn's Disease | Biotech Hunter | Biotech Hunter